FDA Neurology Panel Will Review MTI Onyx PMA Based On Coil Comparison
This article was originally published in The Gray Sheet
Executive Summary
FDA's Neurological Devices Advisory Panel will meet Aug. 5 to review Micro Therapeutics' PMA for Onyx liquid embolic polymer to treat arteriovenous malformations (AVM)
You may also be interested in...
MTI Onyx V. Aneurysm Coil Trial Protocol Revisited; PMA On Track For 2004
Micro Therapeutics' revised inclusion criteria for its U.S. pivotal trial comparing the Onyx LES liquid embolic system with Boston Scientific's GDC Ultrasoft coil to treat brain aneurysms will delay PMA filing by three fiscal quarters, MTI estimates
Stroke Trials Should Include Surrogate Markers Among Endpoints - Panel
Primary endpoints for clinical trials of neurological devices for stroke treatment and/or prevention should include both surrogate markers and clinical outcomes, FDA's Neurological Devices Panel recommended at a Nov. 16 meeting in Rockville, Maryland.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.